EDIT
Editas Medicine, Inc.
Biotechnology · Healthcare · United States
2.67
close · 2026-10-30
value
8
cheaper than peers8
quality
52
stronger fundamentals52
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 8.72× | 58 |
| price to book | 3.89× | 43 |
| cash flow yield, 2 years ago | -33.4% | 26 |
| earnings yield, 2 years ago | -75.7% | 22 |
| cash flow yield, latest year | -40.4% | 21 |
| cash flow yield, 3 years ago | -44.3% | 21 |
| earnings yield, latest year | -67.4% | 16 |
| cash flow yield, 1 year ago | -53.4% | 16 |
| earnings yield, 3 years ago | -120.2% | 14 |
| earnings yield, 1 year ago | -107.9% | 13 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 232.3% | 85 |
| debt to equity | 14.7% | 53 |
| operating margin | -167.3% | 48 |
| return on equity | -118.8% | 21 |
4 of 4 measures available
Facts
| market cap | $410M |
| free cash flow | -$44.3M |
| employees | 87 |
| first trade | 2016-02-03 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-17 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.80 | -2.88 | -2.02 | -3.21 |
| free cash flow | -$165.8M | -$219.1M | -$136.9M | -$181.5M |
| net income | -$160.1M | -$237.1M | -$153.2M | -$220.4M |
| revenue | $40.5M | $32.3M | $78.1M | $19.7M |
| unusual items | -$60.7M | -$12.2M | $0 | $0 |